Luxor’s Mummification Museum Documents 25 Years of Pharaonic Secrets

Statues of cats discovered by Egyptian archaeological team in Giza's Saqqara necropolis, south of Cairo, are displayed. (AFP)
Statues of cats discovered by Egyptian archaeological team in Giza's Saqqara necropolis, south of Cairo, are displayed. (AFP)
TT

Luxor’s Mummification Museum Documents 25 Years of Pharaonic Secrets

Statues of cats discovered by Egyptian archaeological team in Giza's Saqqara necropolis, south of Cairo, are displayed. (AFP)
Statues of cats discovered by Egyptian archaeological team in Giza's Saqqara necropolis, south of Cairo, are displayed. (AFP)

On the eastern shore of the Nile River and the northern side of the Luxor Temple, stands the Mummification Museum, one of the largest specialized museums in Egypt that explores the land of the dead and the golden rays of the sun.

The museum exclusively documents the mysteries of embalming – one of most valuable secrets of ancient Egypt. It is celebrating its 25th anniversary by offering free workshops for visitors to allow them to learn about its history, archeological acquisitions, and boost their touristic and archeological knowledge. The workshops provide presentations that simulate the embalming process and tools in ancient Egypt, coffins, and deities from the other world.

Extending over 2,000 square meters, the Mummification Museum was inaugurated on May 7, 1997. It houses one gallery exhibiting around 73 antiquities providing an inclusive definition of the whole embalming process and explaining the religious value of embalming and the related rituals from the Old Kingdom until the Late Period. It also displays many mummification tools, Canopic jars collection, adorned coffins, amulets, deities’ statues, and funerary drawings.

The museum also exhibits many human mummies, as well as a collection of animal mummies including crocodiles, cats, and fish.

The Mummification Museum is the only museum specialized in documenting the mummification processes in ancient Egypt, said Mohammad Shehata, director general of the museum.

He told Asharq Al-Awsat that “the museum shed lights on the embalming process from death until the end of the burial ceremony, which spanned 70 days.”

“The priests who led the embalming processes were carefully selected based on specific qualifications, including good manners, and good medical and anatomical skills. They carried out embalming processes in the embalming house, or what the ancient Egyptians used to name ‘the beautiful house’, inside the Karnak Temple, where they used to undress the dead before purifying him with the water of the temple’s sacred lake, remove his insides, and cover his body with Natron salt,” explained Shehata.

The brain was extracted from the nasal cavities after breaking the ethmoid bone using a screwdriver-like tool and a spatula, while leaving the heart due to religious beliefs.

Shehata acknowledged the negative impact the coronavirus pandemic and global inflation had on tourism in Luxor. He added that the inauguration of the Avenues of the Sphinxes helped boost tourism for a few months before the eruption of the Russian war on Ukraine.

Among the prominent exhibited antiquities at the museum is the mummy of priest Masherti, son of King Pinedjem from the 21st Dynasty, who served as a senior Priest of Amun in Thebes and an army commander.

The museum also displays a column known as the "spine of God Osiris", mummy cases of High Priest of Amun from the 21st Dynasty, two wooden statues of deities Isis and Nephthys, and wooden boxes used inside tombs to preserve statues.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”